Skip to main content

Table 1 Social, demographic and clinical data of SLE patients in control and therapy groups

From: Psychoanalytic psychotherapy improves quality of life, depression, anxiety and coping in patients with systemic lupus erythematosus: a controlled randomized clinical trial

Patients (n = 80) Control (n = 43) Therapy (n = 37) P value
Age mean (SD)* 42.7 (11.3) 42.0 (12.3) 0.798
Disease duration mean (SD)** 11.6 (8.2) 12.4 (7.8) 0.511
Educationa n (%)*** 0.625
 ≤ 3 years 05 (11.6) 03 (8.1)
 4–8 years 16 (37.2) 10 (27.0)
 9–11 years 05 (11.6) 08 (21.6)
 12–15 years 16 (37.2) 14 (37.8)
 ≥ 16 years 01 (2.3) 02 (5.4)
Socioeconomic classa n (%)*** 0.846
 A/B 00 (.0) 00 (.0)
 C 26 (60.5) 20 (54.1)
 D 12 (27.9) 12 (32.4)
 E 05 (11.6) 05 (13.5)
Race n (%)*** 0.642
 White 22 (54.2) 17 (45.9)
 Afro descendants 21 (45.8) 20 (54.1)
Religion n (%)*** 0.121
 Catholic 17 (39.5) 22 (59.5)
 Evangelic 13 (30.2) 13 (35.1)
 Spiritualist 05 (11.6) 01 (2.7)
 Jehovah witness 04 (9.3) 01 (2.7)
 Buddhist 01 (2.3) 00 (.0)
 No religion 03 (7.0) 00 (.0)
Lupus medications n (%)***
 Azathioprine 11 (25.6) 09 (24.3) 0.897
 Hydroxychloroquine 25 (58.1) 19 (51.4) 0.542
 Prednisone 24 (55.8) 21 (56.8) 0.932
Neuropsychiatric medications n (%)***
 Amitriptyline 07 (16.3) 06 (16.2) 0.994
 Cyclobenzaprine 03 (7.0) 02 (5.4) 0.770
 Fluoxetine 09 (20.9) 07 (18.9) 0.882
SLICC/ACR-DI b n (%)*** 0.055
 Zero 22 (51.2) 11 (29.7)
 1.00 12 (27.9) 17 (45.9)
 2.00 06 (14.0) 02 (5.4)
 3.00 03 (7.0) 04 (10.8)
 4.00 00 (.0) 03 (8.1)
  1. aABIPEME Criteria - Brazilian Association of Market Research Institutes (1995)
  2. bSLICC/ACR-DI - Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage
  3. Index (Range: 0–46)
  4. *t -Student test; **Mann-Whitney test; ***Chi-square test